Brinton Pharmaceutical Ltd. announces the expansion of its global R&D laboratory in the UK



NNA |
Update:
April 22, 2022 7:19 p.m. STI

Pune (Maharashtra) [India]April 22 (ANI/NewsSee): Brinton Pharmaceutical Limited, which has a strong presence in India and globally in 24 countries, has decided to invest in a global research and development center in the UK.
The company plans to invest £30 million over the next five years to strengthen its product pipelines, create 300 highly skilled jobs and develop innovative products for its global consumers.
The proposed life science research and development center in the UK’s North of England region will support the company’s research acceleration in biotechnology, health and science of life. This investment helps the company engage in a thriving life science ecosystem, supporting its global ambitions to develop next-generation healthcare products.
UK-India collaboration:
-The company looks to the UK as a partner to achieve its international aspirations. The UK offers a collaborative business environment dedicated to promoting science and innovation with access to some of the best pharmaceutical talent, excellent global connectivity and a wide range of opportunities in the healthcare sector and life sciences.
UK Prime Minister Boris Johnson said: “Trade and investment between the UK and India creates good jobs and sustains livelihoods in both our countries. I am very pleased that Brinton Pharmaceuticals has decided to join the legions of Indian companies investing in the UK. , energizing our healthcare sector and driving economic growth.”
Rahul Kumar Darda, President and CEO of Brinton, said, “Our long-term business plan is based on research and innovation. The main objective is to generate a high quality portfolio of differentiated niche products that address unmet needs. milestone in our long journey to growth and we are very excited.”
We continually strive to achieve unparalleled operational excellence by leveraging research and development, production, quality and regulatory compliance standards. Our Global Capacity Partnership Pool (GCPP) provides important operational synergy to bring innovations to life, Darda added.
Brinton recently made headlines for its strategic alliance between Heritage Brand Krack Cream and the world’s No. 1 Scholl’s foot care product line.

Market needs:
-The UK is a world leader in life sciences offering companies the right business environment to help them invest and build their global identity in the industry. The country offers a very high-end dedicated research infrastructure to support companies that want to develop cutting-edge therapies and treatment pathways for patients.
-The UK government supports research, development and foreign investment in the life sciences sector through its proactive interventions. The government plans to increase R&D spending to 2.4% of GDP by 2027.
-The UK’s public health system, National Health Service (NHS England) is a key partner for life science companies looking to improve the healthcare facilities and patient care services available to people at home. UK. The NHS has some of the best hospitals and clinicians who can help businesses in their efforts to create affordable, world-class patient care systems. Initiatives around innovation, research and development.
Main characteristics:
-Brinton is committed to developing innovative formulations for consumer healthcare as well as specialty care in dermatological, pediatric, respiratory and family specialties as well as nutraceuticals. The organization has introduced 14 unique formulations in India to address unmet patient needs in the country.
-The company plans to use its global research and development center in the UK to create new affordable products using niche technologies.
-The team understands the critical importance of the highly skilled human capital available in the UK, which can help them develop an innovative portfolio of products for the global life sciences market.
-Brinton Pharmaceuticals has ambitious growth plans for the UK and wants to be a key partner in the UK healthcare ecosystem to synthesize world-class research and innovation interventions leading to the manufacture of cutting-edge medical products .
-The company will also create high value employment opportunities in the various areas and skills of the UK life science industry.
This story is provided by NewsSee. ANI shall in no way be responsible for the content of this article. (ANI/NewsSee)